Loading data for ABCL — first visit, this takes a few seconds.
AbCellera Biologics Inc. (ABCL)
NasdaqGS: ABCL
· 实时价格 · USD
11.15
-0.13 (-1.15%)
收盘价： Sep 04, 2026, 3:59 PM
11.33
-0.87%
盘前: 5:57 AM
股价、关键数字和最新消息，都在这一页。
AbCellera Biologics Inc.（ABCL）股价、分析与数据
-1.11% (1D)
| 买价 | 8.28 |
| 市值 | 3.7B |
| 营收（TTM） | 66.2M |
| 净利润（TTM） | -165M |
| 1.32 | |
| -0.54 | |
| n/a | |
| -15.99 | |
| 市净率（TTM） | 3.91 |
| 市销率（TTM） | 55.97 |
| 财报日期 | Nov 5, 2026 |
| 卖价 | 11.5 |
| 成交量 | 2,607,234 |
| 20日均量 | 7,762,955 |
| 开盘价 | 11.46 |
| 前收盘价 | 11.28 |
| 日内区间 | 10.80 - 11.56 |
| 52周区间 | 2.75 - 12.58 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
公司完整简介财报意外
AbCellera Biologics 已于 Aug 5, 2026 发布季度财报：
- 营收为 $4.05M 低于预期 $0, ， -76.29% 同比下滑.
- 每股收益为 -0.18 低于预期 -0.02, ， -50.00% 同比下滑.
第 1 页，共 2 页